Skip to main content

Dalvance Side Effects

Generic name: dalbavancin

Medically reviewed by Last updated on Jul 29, 2023.

Note: This document contains side effect information about dalbavancin. Some dosage forms listed on this page may not apply to the brand name Dalvance.

Applies to dalbavancin: intravenous powder for solution.

Serious side effects of Dalvance

Along with its needed effects, dalbavancin (the active ingredient contained in Dalvance) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking dalbavancin:

Less common

Other side effects of Dalvance

Some side effects of dalbavancin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to dalbavancin: intravenous powder for injection.


The most common adverse reactions in adult patients were nausea, headache, and diarrhea; these were generally of mild or moderate severity.[Ref]


Uncommon (0.1% to 1%): Flushing, phlebitis

Frequency not reported: Wound hemorrhage[Ref]


Common (1% to 10%): Rash, pruritus

Uncommon (0.1% to 1%): Urticaria

Frequency not reported: Petechiae, skin reactions[Ref]


Common (1% to 10%): Nausea, diarrhea, vomiting

Uncommon (0.1% to 1%): Constipation, abdominal pain, dyspepsia, abdominal discomfort, Clostridioides difficile colitis, oral candidiasis

Frequency not reported: Gastrointestinal hemorrhage, melena, hematochezia, C difficile-associated diarrhea[Ref]


Uncommon (0.1% to 1%): Vulvovaginal mycotic infection, urinary tract infection, vulvovaginal pruritus


Uncommon (0.1% to 1%): Anemia, thrombocytosis, eosinophilia, leukopenia, neutropenia, increased platelet count

Frequency not reported: Hemorrhagic anemia, thrombocytopenia, increased INR, spontaneous hematoma


Uncommon (0.1% to 1%): Increased ALT, increased AST, abnormal liver function test, increased transaminases, increased hepatic enzyme, increased GGT

Frequency not reported: Hepatotoxicity, increased hepatic transaminases[Ref]

Among patients with normal baseline ALT levels treated with this drug, 17 (0.8%) had post-baseline ALT elevations greater than 3 times the upper limit of normal (3 x ULN), including 5 patients with post-baseline ALT values greater than 10 x ULN; among patients with normal baseline ALT levels treated with comparators, 2 (0.2%) had post-baseline ALT elevations greater than 3 x ULN, but not greater than 10 x ULN. Of the 17 patients treated with this drug, 15 had underlying conditions that could affect liver enzymes (including chronic viral hepatitis, history of alcohol abuse, metabolic syndrome). In 1 trial, 1 patient treated with this drug had post-baseline ALT elevations greater than 20 x ULN. ALT elevations were reversible in all patients with follow-up assessments.[Ref]


Rare (0.01% to 0.1%): Anaphylactoid reaction

Frequency not reported: Serious hypersensitivity (anaphylactic)[Ref]


Uncommon (0.1% to 1%): Decreased appetite, increased blood uric acid

Frequency not reported: Hypoglycemia[Ref]

Nervous system

Common (1% to 10%): Headache

Uncommon (0.1% to 1%): Dizziness, dysgeusia[Ref]


Uncommon (0.1% to 1%): Infusion-related reactions, fungal infection, increased blood lactate dehydrogenase, increased blood alkaline phosphatase, increased body temperature

Frequency not reported: Pyrexia

Postmarketing reports: Back pain (as an infusion-related reaction)


Uncommon (0.1% to 1%): Insomnia


Uncommon (0.1% to 1%): Cough

Rare (0.01% to 0.1%): Bronchospasm[Ref]


1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Product Information. Dalvance (dalbavancin). Durata Therapeutics, Inc. 2014.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.